I-Mab’s Q2 2025: Clinical Progress and Financial Strength

I-Mab Adr ( (IMAB) ) has released its Q2 earnings. Here is a breakdown of the information I-Mab Adr presented to its investors.

I-Mab is a U.S.-based global biotech company specializing in the development of precision immuno-oncology agents for cancer treatment, with a focus on innovative therapies like givastomig for Claudin 18.2-positive gastric cancers.

In its latest earnings report for the second quarter of 2025, I-Mab highlighted significant progress in its clinical pipeline, particularly with its lead candidate, givastomig. The company presented positive Phase 1b data at the ESMO GI 2025, showing an 83% objective response rate in combination with immunochemotherapy for first-line metastatic gastric cancers. Additionally, I-Mab strengthened its financial position with a successful underwritten offering, raising approximately $61.2 million.

Key financial metrics revealed a reduction in research and development expenses to $3.3 million for the quarter, down from $5.2 million in the same period last year, attributed to streamlined clinical activities. Administrative expenses also decreased significantly to $3.8 million from $11.9 million, primarily due to lower legal and employee-related costs. Despite a net loss of $5.5 million for the quarter, the company maintained a robust cash position, with a pro-forma cash balance of $226.8 million expected to support operations through the end of 2028.

Strategically, I-Mab completed the enrollment of its Phase 1b dose expansion study for givastomig and anticipates presenting topline data in the first quarter of 2026. The company also enhanced its intellectual property portfolio through the acquisition of Bridge Health, securing upstream rights to the Claudin 18.2 parental antibody.

Looking ahead, I-Mab remains focused on advancing its clinical programs and leveraging its strong cash reserves to deliver meaningful clinical data. The management is optimistic about the potential of givastomig and other pipeline candidates to improve patient outcomes in oncology.